CTMX Q4 2022 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+2.0% YoY

Gross Profit

$20M100.0% margin

Operating Income

-$10M-47.2% margin

Net Income

-$9M-43.6% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+80.5%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$261M

Total Liabilities

$347M

Stockholders' Equity

-$86M

Cash & Equivalents

$194M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$20M	+2.0%
Gross Profit	$20M	$18M	+10.3%
Operating Income	-$10M	-$26M	+63.9%
Net Income	-$9M	-$26M	+66.5%